Australia's most trusted
source of pharma news
Posted 14 May 2025 PM
US-based non-profit, Critical Path Institute, has invested $1.25 million in a new treatment for advanced and therapy-resistant prostate cancer, at the University of Queensland.
The grant falls under Critical Path Institute’s Translation Therapeutics Accelerator program (TRxA), which seeks to advance cutting-edge therapeutics from the lab to patients. The funding injection will cover critical preclinical studies, process optimisation, drug substance manufacturing and safety studies, paving the way for the drug dubbed QED-203 to potentially advance to human clinical trials.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.